Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Horst Prescher"'
Publikováno v:
Journal of Medicinal Chemistry. 65:10588-10610
Autor:
Piyali Dutta, Andrea McGranaghan, Isabelle Keller, Yogesh Patil, Nicholas Mulholland, Vikrant Murudi, Horst Prescher, Alex Smith, Nessa Carson, Chris Martin, Paul Cox, Daniel Stierli, Mohamed Boussemghoune, Fabien Barreteau, Jérôme Cassayre, Edouard Godineau
Publikováno v:
Green Chemistry. 24:3943-3956
A two-year collective effort towards the reduction by 50% of the usage of 7 hazardous solvents (Green Chemistry Principle #5) within a large-scale industrial R&D organization.
Autor:
Horst, Prescher, Astrid, Schweizer, Martin, Frank, Elena, Kuhfeldt, Julia, Ring, Lars, Nitschke
Publikováno v:
Journal of medicinal chemistry. 65(15)
Significant interest in the development of high-affinity ligands for Siglecs exists due to the various therapeutically relevant functions of these proteins. Here, we report a new strategy to develop and design Siglec ligands as disialyl-oligosacchari
Publikováno v:
ChemBioChem. 18:1216-1225
CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22-ligand-targeted nanoparticles with therapeutic func
Autor:
Ina Dix, Horst Prescher, Guido Koch, Frank Petersen, Tim Schuhmann, Dimitrios Lizos, Peter Ertl, Meir Glick, Alex Bussenault
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:921-925
A fragment library consisting of 3D-shaped, natural product-like fragments was assembled. Library construction was mainly performed by natural product degradation and natural product diversification reactions and was complemented by the identificatio
Autor:
Carsten Watzl, Reinhard Brossmer, Horst Prescher, Stephan Gütgemann, Elena Kuhfeldt, Lars Nitschke, Martin Frank, Astrid Schweizer
Publikováno v:
Journal of medicinal chemistry. 60(3)
Natural killer cells are able to directly lyse tumor cells, thereby participating in the immune surveillance against cancer. Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by the immune system. A prominent e
Publikováno v:
European Journal of Immunology. 42:2792-2802
CD22 is an inhibitory co-receptor of the B-cell receptor (BCR) on B cells. Since CD22 is ubiquitously expressed in the B-cell lineage and CD22 endocytosis can be triggered efficiently, antibodies and antibody-based immunotoxins against CD22 are used
Autor:
Raquel Ruivo, Hugues-Olivier Bertrand, Nicolas Pietrancosta, Bruno Gasnier, Reinhard Brossmer, Cécile Debacker, Corinne Sagné, Christine Anne, Horst Prescher, Francine Acher
Publikováno v:
Journal of Biological Chemistry
Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2012, 287 (14), pp.11489-11497. ⟨10.1074/jbc.M111.313056⟩
Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2012, 287 (14), pp.11489-11497. ⟨10.1074/jbc.M111.313056⟩
Secondary active transporters from the SLC17 protein family are required for excitatory and purinergic synaptic transmission, sialic acid metabolism, and renal function, and several members are associated with inherited neurological or metabolic dise
Autor:
Reinhard Brossmer, Stephan Gütgemann, Carsten Watzl, Horst Prescher, Elena Kuhfeldt, Martin Frank
Publikováno v:
Bioorganicmedicinal chemistry. 23(17)
Siglecs (sialic acid recognizing immunoglobulin like lectins) are a family of lectins with specificity for sialic acid containing carbohydrates. Synthetic sialic acid derivatives with high affinity proved useful to unravel the biological role of the
Publikováno v:
European journal of immunology. 42(10)
CD22 is an inhibitory co-receptor of the B-cell receptor (BCR) on B cells. Since CD22 is ubiquitously expressed in the B-cell lineage and CD22 endocytosis can be triggered efficiently, antibodies and antibody-based immunotoxins against CD22 are used